Update on angiogenesis inhibitors

Current Opinion in Oncology

Volumn 17, Issue 6, 2005, Pages 578-583

  Zakarija, Anaadriana ^a   Soff, Gerald ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Angiogenesis; Cancer treatment; Vascular endothelial growth factor

Indexed keywords

AE 941; ALANINE AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CAPECITABINE; CARBOPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PACLITAXEL; PLATINUM DERIVATIVE; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; VANDETANIB; VASCULOTROPIN; VATALANIB;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL THROMBOEMBOLIC EVENT; ARTERY THROMBOSIS; ARTHRALGIA; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; LETHARGY; LUNG EMBOLISM; METASTASIS; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; THROMBOSIS; TOXICITY; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNITED STATES; VEIN THROMBOSIS; VOMITING; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; COLORECTAL NEOPLASMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHTHALAZINES; PIPERIDINES; PYRIDINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 27644584796     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000183672.15133.ab     Document Type: Review

References (43)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
2. Rak J, Kerbel RS. Prospects and progress in the development of antiangiogenic agents. In: Rosenberg SA, ed, ed. In: Principles & Practice of Biologic Therapy of Cancer, 3rd edition. Philadelphia, PA: Lippincott, Williams, & Wilkins, 2002.
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676. Comprehensive overview of the VEGF signaling pathway.
4. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9-22.
5. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9(Suppl 1):2-10.
6. Padro T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002; 16: 1302-1310.
7. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996; 56:2013-2016.
8. Guidi AJ, Abu-Jawdeh G, Tognazzi K, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 1996; 78:454-460.
9. Harada Y, Ogata Y, Shirouzu K. Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer. Int J Clin Oncol 2001; 6:221-228.
10. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002; 86: 558-563.
11. Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001; 19:432-441.
12. Bando H, Weich HA, Brokelmann M, et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer 2005; 92:553-561.
13. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol 1997; 15:826-832.
14. Fine BA, Valente PT, Feinstein GI, Dey T. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol Oncol 2000; 76:33-39.
15. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-844.
16. Millauer B, Longhi MP, Plate KH, et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996; 56: 1615-1620.
17. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-5218.
18. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65.
19. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342. Pivotal trial demonstrating improved survival in metastatic colorectal cancer patients treated with bevacizumab.
20. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with Fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23:3502-3508. Clinical trial demonstrating efficacy of bevacizumab in patients with metastatic colorectal cancer.
21. Giantonio BJ, Catalane PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract]. J Clin Oncol, Proc Annu Meet Am Soc Clin Oncol 2005; 23:2.
22. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191.
23. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799.
24. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
25. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19:843-850.
26. Bevacizumab. (Avastin) Package Insert. San Francisco, CA: Genentech, February, 2004.
27. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21:3542. (author reply 3543)
28. Skillings JR, Johnson DH, Miller K, et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials of bevacizumab with chemotherapy [abstract]. J Clin Oncol, Proc Annu Meet Am Soc Clin Oncol 2005; 23:3019.
29. Holden SN, Ryan E, Kearns A, et al. Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (VEGF-A) in patients with metastatic colorectal cancer [abstract]. J Clin Oncol, Proc Annu Meet Am Soc Clin Oncol 2005; 23:3555.
30. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60:2178-2189.
31. Thomas AL, Morgan B, Horsfield MA, et al. Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer. J Clin Oncol 2005; 23:4162-4171. Preliminary data on a new angiogenesis inhibitor that describes use of surrogate assessment of biologic activity by dynamic contrast-enhanced MRI.
32. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon ore rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) [abstract]. J Clin Oncol Proc, Annu Meet Am Soc Clin Oncol 2005; 23: LBA3.
33. Trarbach T, Schleucher N, Tewes M, et al. Phase I/II study of PTK787/ZK 222584, a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer [abstract]. J Clin Oncol, Proc Annu Meet Am Soc Clin Oncol 2005; 23:3605.
34. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-3964.
35. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005; 16:558-565.
36. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9:1546-1556.
37. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005; 16:1391-1397.
38. Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase Il trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005; 11:3369-3376.
39. Heymach JV, Johnson BE, Rowbottom JA, et al. A randomized, placebo-controlled Phase II trial of ZD6474 plus docetaxel, in patients with NSCLC [abstract]. J Clin Oncol, Proc Annu Meet Am Soc Clin Oncol 2005; 23:3023.
40. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
41. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-972.
42. Ratain MJ, Eisen T, Stadler WM, et al. Final findings from a Phase II, placebo-controlled, randomized discontinuation trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma [abstract]. J Clin Oncol, Proc Annu Meet Am Soc Clin Oncol 2005; 23:4544.
43. Escudier B, Szczylik C, Eisen T, et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma [abstract]. J Clin Oncol, Proc Annu Meet Am Soc Clin Oncol 2005; 23:LBA4510.